Guangzhou Shunjian Biomedical Technology

Guangzhou Shunjian Biomedical Technology is a Chinese biotechnology company focused on the development of innovative small molecule drugs for oncology. Founded in 2012 by Dr. Lu Shan, the company is best known for developing Olverembatinib (HQP1351), a third-generation BCR-ABL inhibitor targeting drug-resistant chronic myeloid leukemia. In 2016, the company was acquired by Ascentage Pharma, serving as a key research and development subsidiary. Its lead product, Olverembatinib, has received regulatory approval in China for the treatment of adult patients with T315I-mutant chronic phase or accelerated phase CML. The company continues to operate within the Ascentage Pharma group, contributing to the advancement of therapies for hematologic malignancies.